Investors

Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries.


Stock Quote
XTNT (Common Stock)
Price$0.44
Change (%) + 0.01 (2.33%)
Volume91,737
Data as of 05/26/17 4:02 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart


Recent News
DateTitle 
05/26/17Xtant Medical Announces Rescheduling of Annual Meeting
BELGRADE, Mont., May 26, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its board of directors has rescheduled the Company's annual meeting of stockholders, originally scheduled for June 21, 2017, to a later date, as the Company continues to evaluate its strategic alternatives. The Company will announce a new annual meeting date and record date when they are determin... 
05/16/17Xtant Medical Enters into Licensing Agreement for Sites Medical’s OsteoSync Ti Technology
BELGRADE, Mont., May 16, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced it has entered into a licensing agreement with Sites Medical LLC, for utilization of their proprietary OsteoSync™ Ti technology, a best-in-class porous titanium scaffold. "We are very excited to work with Sites Medical," said Carl O'Connell, CEO of Xtant Medical.... 
05/12/17Xtant Medical Announces OrbiMed Financing and Engagement of Aurora Management Partners
BELGRADE, Mont., May 12, 2017 (GLOBE NEWSWIRE) -- Xtant™ Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced it has entered into an amendment to its senior credit facility with affiliates of OrbiMed Advisors (“OrbiMed”) for a financing of up to $15 million with the proceeds being used to pay off its outstanding balance of approximately $9 million under its accounts receivable credit facility with Silicon Val... 
05/09/17Xtant™ Medical Reports First Quarter Revenue of $22.1 million, 5% Growth Compared to the Prior Year Period
First Quarter 2017 Highlights: Consolidated total revenue increased 5.3% to $22.1 million compared to first quarter 2016 revenue of $21.0 million Consolidated gross profit increased 10.1% to $15.5 million compared to first quarter 2016 gross profit of $14.1 million Consolidated gross margins improved to 70.3%, compared to 67.2% reported in the first quarter of 2016 The Company reported an EBITDA gain of approximately $577,000 for the first quarter of 2017 BELGRADE, Mont., May ... 
More


Upcoming Events
DateTitle
06/21/17 8:00 a.m. MT
Xtant Medical Holdings Inc 2017 Annual Meeting of Stockholders
More

Receive Email Alerts
Sign up to receive email alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your email address and click Submit.